Literature DB >> 1287854

Targeted delivery of antisense oligonucleotides by molecular conjugates.

B A Bunnell1, F K Askari, J M Wilson.   

Abstract

Antisense oligonucleotides efficiently inhibit gene expression in vitro; however, the successful therapeutic application of this technology in vivo will require the development of improved delivery systems. In this report we describe a technique that efficiently delivers antisense oligonucleotides into cells using molecular conjugates. This technique, which was initially developed for the delivery of eukaryotic genes, is based on the construction of DNA-protein complexes that are recognized by the liver-specific asialoglycoprotein receptor. Binding of poly(L-lysine)-asialoorosomucoid (AsOR) protein conjugates with phosphorothioate antisense oligonucleotides to chloramphenicol acetyltransferase (CAT) led to the formation of 50- to 150-nm toroids. Exposure of the antisense molecular complexes (3 microM oligonucleotide) to NIH 3T3 cells genetically modified to express both the AsOR receptor and CAT, inhibited CAT expression by 54%, which was completely blocked by excess AsOR. Equivalent inhibition of CAT activity with purified oligonucleotide alone was observed at a 30 microM concentration. Furthermore, examination of the cells using indirect immunofluorescence for the presence of CAT protein showed 28% of cells exposed to the molecular conjugates lacked any detectable CAT enzyme. Cells exposed to oligonucleotide alone showed a highly variable staining pattern, and only a few of the cells were completely void of CAT protein. Together these data demonstrate that molecular conjugates provide a highly specific and efficient system for the delivery of antisense oligonucleotides.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1287854     DOI: 10.1007/bf01232652

Source DB:  PubMed          Journal:  Somat Cell Mol Genet        ISSN: 0740-7750


  10 in total

1.  Antisense delivery using protamine-oligonucleotide particles.

Authors:  M Junghans; J Kreuter; A Zimmer
Journal:  Nucleic Acids Res       Date:  2000-05-15       Impact factor: 16.971

2.  Targeted delivery of oligodeoxynucleotides to parenchymal liver cells in vivo.

Authors:  E A Biessen; H Vietsch; E T Rump; K Fluiter; J Kuiper; M K Bijsterbosch; T J van Berkel
Journal:  Biochem J       Date:  1999-06-15       Impact factor: 3.857

3.  Evaluation of adjuvants that enhance the effectiveness of antisense oligodeoxynucleotides.

Authors:  J A Hughes; A I Aronsohn; A V Avrutskaya; R L Juliano
Journal:  Pharm Res       Date:  1996-03       Impact factor: 4.200

4.  DNA condensation for gene therapy as monitored by atomic force microscopy.

Authors:  H G Hansma; R Golan; W Hsieh; C P Lollo; P Mullen-Ley; D Kwoh
Journal:  Nucleic Acids Res       Date:  1998-05-15       Impact factor: 16.971

Review 5.  Antigene, ribozyme and aptamer nucleic acid drugs: progress and prospects.

Authors:  R A Stull; F C Szoka
Journal:  Pharm Res       Date:  1995-04       Impact factor: 4.200

6.  The transmembrane domain of diphtheria toxin improves molecular conjugate gene transfer.

Authors:  K J Fisher; J M Wilson
Journal:  Biochem J       Date:  1997-01-01       Impact factor: 3.857

7.  Delivery of antisense oligodeoxyribonucleotides against the human epidermal growth factor receptor into cultured KB cells with liposomes conjugated to folate via polyethylene glycol.

Authors:  S Wang; R J Lee; G Cauchon; D G Gorenstein; P S Low
Journal:  Proc Natl Acad Sci U S A       Date:  1995-04-11       Impact factor: 11.205

Review 8.  Gene therapy for cancer: from the laboratory to the patient.

Authors:  G Kouraklis
Journal:  Dig Dis Sci       Date:  2000-06       Impact factor: 3.487

Review 9.  The use of synthetic polymers for delivery of therapeutic antisense oligodeoxynucleotides.

Authors:  Traian V Chirila; Piroska E Rakoczy; Kerryn L Garrett; Xia Lou; Ian J Constable
Journal:  Biomaterials       Date:  2002-01       Impact factor: 12.479

Review 10.  Antisense inhibition of virus infections.

Authors:  R E Kilkuskie; A K Field
Journal:  Adv Pharmacol       Date:  1997
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.